+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

  • PDF Icon

    Report

  • 75 Pages
  • April 2025
  • Region: Global
  • Kuick Research
  • ID: 5720901
UP TO OFF until Apr 15th 2025

Report Highlights & Findings:

  • First VISTA Inhibitor Drug Approval By 2028
  • US Dominating Global VISTA Inhibitor Clinical Trials Landscape
  • Insight On Ongoing Clinical Trials By Company, Country, Indication & Phase
  • Key Drugs Clinical Study Initiation & Completion Year Overview
  • Global & Regional Market Development Insight By Indication
  • Global VISTA Inhibitors Market Dynamics & Competitive Landscape

The landscape of cancer immunotherapy has witnessed remarkable transformations in recent years, with immune checkpoint inhibitors revolutionizing treatment approaches for various malignancies. With the massive success of first generation immune checkpoint inhibitors, such as pembrolizumab and Nivolumab, researchers have now focused their efforts in identifying newer immune checkpoint proteins. Among the emerging next-generation targets in this innovative field is the V-domain immunoglobulin suppressor of T cell activation (VISTA), which represents a promising yet under-explored avenue for potential therapeutic interventions across a range of indications.

VISTA, a critical immune checkpoint protein, plays a nuanced role in regulating immune responses, particularly within the tumor microenvironment. Unlike more extensively studied checkpoint molecules like PD-1 and CTLA-4, VISTA remains a relatively nascent target with significant untapped potential. Researchers have increasingly recognized its importance in modulating T cell activation and suppressing anti-tumor immune responses, making it an intriguing candidate for targeted immunotherapeutic strategies.

The current immunotherapy landscape demonstrates considerable promise for VISTA targeted approaches, drawing parallels with the remarkable success of existing immune checkpoint inhibitors. The groundbreaking achievements of PD-1 and CTLA-4 inhibitors have paved the way for more sophisticated and precise immunomodulatory interventions. These precedents provide robust scientific validation and investor confidence in exploring novel checkpoint targets like VISTA, suggesting a potentially transformative therapeutic approach.

Among the most promising developments in VISTA targeted therapy is CA-170, an innovative oral small molecule developed by Aurigene Oncology and Curis. This compound represents a sophisticated dual inhibitor targeting both VISTA and PD-L1, offering several compelling advantages over traditional antibody-based approaches. The molecule’s oral administration format, reduced complexity, and potential for more manageable immune-related adverse events distinguish it from conventional immunotherapeutic strategies.

The strategic collaboration between Aurigene and Curis highlights the significant interest and potential commercial viability of VISTA targeted therapies. By dividing development rights across different geographical regions, the partnership underscores the global scientific community’s recognition of VISTA’s therapeutic potential. The ongoing late-phase clinical trials, particularly the phase 2b/3 studies investigating CA-170’s efficacy in non-small cell lung cancer, represent a critical milestone in understanding the molecule’s clinical utility.

Preclinical and early stage research has unveiled VISTA’s complex immunomodulatory mechanisms. Unlike some checkpoint proteins, VISTA exhibits unique characteristics in suppressing T cell responses, suggesting nuanced implications for cancer immunotherapy. Preliminary studies indicate that VISTA’s inhibition could potentially reinvigorate anti-tumor immune responses, offering a complementary or alternative approach to existing checkpoint blockade strategies.

The lack of approved VISTA-targeted therapies presents both a challenge and an opportunity for researchers and pharmaceutical developers. The uncharted nature of this therapeutic domain invites innovative approaches and allows for creative exploration of VISTA’s potential mechanisms. Researchers are particularly intrigued by VISTA’s potential in overcoming resistance mechanisms observed with other checkpoint inhibitors, potentially offering new hope for patients with treatment-resistant malignancies.

Scientific interest in VISTA extends beyond oncology, with emerging research suggesting potential applications in autoimmune disorders and inflammatory conditions. This broader therapeutic landscape further amplifies the molecule’s significance and underscores the importance of continued investigative efforts. The multifaceted nature of VISTA’s immunomodulatory functions presents a complex yet exciting frontier for translational research.

As the scientific community continues to unravel VISTA’s intricate roles in immune regulation, the coming years are likely to witness accelerated research and clinical development. The potential for developing targeted therapies that can modulate immune responses with greater precision represents a significant advancement in personalized medicine. While challenges remain, the foundational research and ongoing clinical investigations paint an optimistic picture for VISTA-targeted therapeutic strategies.

Table of Contents

1. VISTA As Emerging Immune Checkpoint
1.1 What Is VISTA Inhibition?
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism Of Action Of VISTA Inhibitors

2. VISTA As Inhibitory & Costimulatory Checkpoint
2.1 VISTA As Inhibitory Immune Checkpoint
2.2 VISTA As Costimulatory Checkpoint
2.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors

3. Significance Of VISTA In Disease Progressiopn & Cure
3.1 Role Of VlSTA In Facilitating Cancer Progression
3.2 VISTA As Potential Cancer Biomarker
3.3 VISTA As Therapeutic Target In Autoimmune Diseases

4. Global VISTA Inhibitors Market & Clinical Development Outlook
4.1 Current Scenario
4.2 Future Opportunities

5. VISTA Targeted Therapies Trends & Clinical Innovation By Indication
5.1 Solid Cancers
5.2 Hematological Cancers
5.3 Autoimmune & Inflammatory Disorders

6. VISTA Targeted Therapies Trends & Clinical Innovation By Region
6.1 US
6.2 Europe
6.3 India
6.4 Australia

7. Global VISTA Inhibitors Clinical Trials Overview
7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase

8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase III

9. Global VISTA Inhibitors Market Dynamics
9.1 Market Drivers
9.2 Market Challenges

10. Competitive Landscape
10.1 Aurigene Discovery Technologies
10.2 Curis
10.3 Hummingbird Bioscience
10.4 Kineta
10.5 PharmAbcine
10.6 Sensei Biotherapeutics

List of Figures and Tbales
Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 2-1: VISTA - Role In Cancer Immunotherapy
Figure 2-2: VISTA - Role In Autoimmune Diseases
Figure 2-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 3-1: VISTA Interaction With Immune Cells
Figure 3-2: VISTA - Mechanisms Of Immune Suppression
Figure 3-3: Dual Role Of VISTA In Cancer
Figure 3-4: VISTA As Predictive Biomarker
Figure 3-5: Autoimmune Diseases - VISTA Agonism
Figure 4-1: Future Market Opportunities
Figure 5-1: Solid Tumors - VISTA Role In Tumor Immune Evasion
Figure 5-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study - Initiation & Completion Year
Figure 5-3: HMBD-002-V4C26-01 Phase 1/2 (NCT05082610) Study - Initiation & Completion Year
Figure 5-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
Figure 5-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
Figure 5-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
Figure 5-7: Kings College London & Dartmouth College VISTA Patent - Grant & Expiration Year
Figure 6-1: MarkV-01/KEYNOTE-E80 Phase 1 (NCT05957081) Study - Initiation & Completion Year
Figure 7-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2025
Figure 7-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2025
Figure 7-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2025
Figure 7-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2025
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints
Table 5-1: VISTA - Role In Autoimmune & Inflammatory Disorders
Table 6-1: US - Ongoing Clinical Trials for VISTA Inhibitors

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  •    Aurigene Discovery Technologies
  •   Curis
  •   Hummingbird Bioscience
  •   Kineta
  •   PharmAbcine
  •   Sensei Biotherapeutics